FATE

Fate Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↑ 6/10
  • Value↓ 0/10
Fate Therapeutics sales and earnings growth
FATE Growth
Good
  • Revenue Y/Y↓ -53.31%
  • EPS Y/Y↑ 27.33%
  • FCF Y/Y↑ 13.93%
Fate Therapeutics gross and profit margin trends
FATE Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -2056.80%
  • ROIC 5Y↓ -35.62%
Fate Therapeutics net debt vs free cash flow
FATE Risk
Great
  • Debt / Equity↓ 0.4
  • Debt / FCF↓ 0.3
  • Interest coverage↓ NA

Fate Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks